178 related articles for article (PubMed ID: 31832725)
1. Elevations in Cortical Porosity Occur Prior to Significant Rise in Serum Parathyroid Hormone in Young Female Mice with Adenine-Induced CKD.
Metzger CE; Swallow EA; Allen MR
Calcif Tissue Int; 2020 Apr; 106(4):392-400. PubMed ID: 31832725
[TBL] [Abstract][Full Text] [Related]
2. Strain-specific alterations in the skeletal response to adenine-induced chronic kidney disease are associated with differences in parathyroid hormone levels.
Metzger CE; Swallow EA; Stacy AJ; Allen MR
Bone; 2021 Jul; 148():115963. PubMed ID: 33878503
[TBL] [Abstract][Full Text] [Related]
3. Adenine-induced chronic kidney disease induces a similar skeletal phenotype in male and female C57BL/6 mice with more severe deficits in cortical bone properties of male mice.
Metzger CE; Swallow EA; Stacy AJ; Allen MR
PLoS One; 2021; 16(4):e0250438. PubMed ID: 33891630
[TBL] [Abstract][Full Text] [Related]
4. Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.
Clinkenbeard EL; Noonan ML; Thomas JC; Ni P; Hum JM; Aref M; Swallow EA; Moe SM; Allen MR; White KE
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830862
[TBL] [Abstract][Full Text] [Related]
5. Reversing cortical porosity: Cortical pore infilling in preclinical models of chronic kidney disease.
Metzger CE; Swallow EA; Stacy AJ; Tippen SP; Hammond MA; Chen NX; Moe SM; Allen MR
Bone; 2021 Feb; 143():115632. PubMed ID: 32927105
[TBL] [Abstract][Full Text] [Related]
6. The combination of aging and chronic kidney disease leads to an exacerbated cortical porosity phenotype.
Tippen SP; Metzger CE; Swallow EA; Sacks SA; Wallace JM; Allen MR
Bone; 2022 Jan; 154():116228. PubMed ID: 34624561
[TBL] [Abstract][Full Text] [Related]
7. Parathyroid suppression therapy normalizes chronic kidney disease-induced elevations in cortical bone vascular perfusion: a pilot study.
Aref MW; Swallow EA; Metzger CE; Chen N; Moe SM; Allen MR
Osteoporos Int; 2019 Aug; 30(8):1693-1698. PubMed ID: 31069439
[TBL] [Abstract][Full Text] [Related]
8. Osteocytes' expression of the PTH/PTHrP receptor has differing effects on endocortical and periosteal bone formation during adenine-induced CKD.
Gardinier JD; Daly-Seiler CS; Zhang C
Bone; 2020 Apr; 133():115186. PubMed ID: 31987988
[TBL] [Abstract][Full Text] [Related]
9. Evocalcet Rescues Secondary Hyperparathyroidism-driven Cortical Porosity in CKD Male Rats.
Hasegawa T; Tokunaga S; Yamamoto T; Sakai M; Hongo H; Kawata T; Amizuka N
Endocrinology; 2023 Feb; 164(4):. PubMed ID: 36718587
[TBL] [Abstract][Full Text] [Related]
10. RANKL/OPG system regulation by endogenous PTH and PTH1R/ATF4 axis in bone: Implications for bone accrual and strength in growing rats with mild uremia.
Znorko B; Pawlak D; Oksztulska-Kolanek E; Domaniewski T; Pryczynicz A; Roszczenko A; Rogalska J; Lipowicz P; Doroszko M; Brzoska MM; Pawlak K
Cytokine; 2018 Jun; 106():19-28. PubMed ID: 29529595
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of RANKL improves the skeletal phenotype of adenine-induced chronic kidney disease in mice.
Metzger CE; Kittaka M; LaPlant AN; Ueki Y; Allen MR
JBMR Plus; 2024 Feb; 8(2):ziae004. PubMed ID: 38505524
[TBL] [Abstract][Full Text] [Related]
12. Cortical porosity development and progression is mitigated after etelcalcetide treatment in an animal model of chronic kidney disease.
Swallow EA; Metzger CE; Newman CL; Chen NX; Moe SM; Allen MR
Bone; 2022 Apr; 157():116340. PubMed ID: 35085840
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of GSK-3β increases trabecular bone volume but not cortical bone volume in adenine-induced uremic mice with severe hyperparathyroidism.
Tatsumoto N; Arioka M; Yamada S; Takahashi-Yanaga F; Tokumoto M; Tsuruya K; Kitazono T; Sasaguri T
Physiol Rep; 2016 Nov; 4(21):. PubMed ID: 27803315
[TBL] [Abstract][Full Text] [Related]
14. Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Sato H; Goto M; Nishimura G; Morimoto N; Tokushima H; Horii Y; Takahashi N
Bone; 2023 Feb; 167():116613. PubMed ID: 36395959
[TBL] [Abstract][Full Text] [Related]
15. Combining raloxifene and mechanical loading improves bone composition and mechanical properties in a murine model of chronic kidney disease (CKD).
Surowiec RK; Reul ON; Chowdhury NN; Rai RK; Segvich D; Tomaschke AA; Damrath J; Jacobson AM; Allen MR; Wallace JM
Bone; 2024 Jun; 183():117089. PubMed ID: 38575047
[TBL] [Abstract][Full Text] [Related]
16. Endogenous parathyroid hormone-related protein compensates for the absence of parathyroid hormone in promoting bone accrual in vivo in a model of bone marrow ablation.
Zhu Q; Zhou X; Zhu M; Wang Q; Goltzman D; Karaplis A; Miao D
J Bone Miner Res; 2013 Sep; 28(9):1898-911. PubMed ID: 23716486
[TBL] [Abstract][Full Text] [Related]
17. Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice.
Piemontese M; Xiong J; Fujiwara Y; Thostenson JD; O'Brien CA
Am J Physiol Endocrinol Metab; 2016 Sep; 311(3):E587-93. PubMed ID: 27460899
[TBL] [Abstract][Full Text] [Related]
18. Cortical porosity is elevated after a single dose of zoledronate in two rodent models of chronic kidney disease.
Swallow EA; Metzger CE; Chen NX; Wallace JM; Tippen SP; Kohler R; Moe SM; Allen MR
Bone Rep; 2022 Jun; 16():101174. PubMed ID: 35252482
[TBL] [Abstract][Full Text] [Related]
19. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
Avbersek-Luznik I; Balon BP; Rus I; Marc J
Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
[TBL] [Abstract][Full Text] [Related]
20. Rapid cortical bone loss in patients with chronic kidney disease.
Nickolas TL; Stein EM; Dworakowski E; Nishiyama KK; Komandah-Kosseh M; Zhang CA; McMahon DJ; Liu XS; Boutroy S; Cremers S; Shane E
J Bone Miner Res; 2013 Aug; 28(8):1811-20. PubMed ID: 23456850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]